Regulation of the Balance between Concentric and Eccentric Cardiac Hypertrophy by a CDC14A-KMT5A Signaling Pathway

This study identifies the CDC14A-KMT5A signaling pathway as a critical molecular switch that regulates the balance between concentric and eccentric cardiac hypertrophy through H4K20 mono-methylation-mediated epigenomic control, suggesting CDC14A inhibition as a potential therapeutic strategy for dilated cardiomyopathy.

The Gist

The Big Picture: The Heart's Shape-Shifting Problem

Imagine your heart is a house. When the house faces a storm (like high blood pressure or a genetic glitch), it tries to reinforce itself. But there are two ways it can do this, and they lead to very different outcomes:

1. Concentric Remodeling (The "Thick-Walled Fortress"): The walls get super thick, but the rooms inside stay the same size. This is like adding more layers of brick to the outside of a house. It's strong, but it's stiff and doesn't pump blood as well. This often leads to heart failure where the heart is too stiff to relax.
2. Eccentric Remodeling (The "Stretched Balloon"): The walls get thin and stretchy, and the rooms inside get huge. This is like blowing up a balloon until the rubber is paper-thin. The heart pumps weakly because the walls are too floppy. This is called Dilated Cardiomyopathy (DCM), a major cause of heart failure.

Scientists have long known that these changes happen, but they didn't know exactly how the heart decides which shape to take. This paper discovers the "switch" that controls this decision.

---

The Characters in Our Story

To understand the discovery, let's meet the three main characters in this cellular drama:

1. CDC14A (The Brake Pedal): Think of this protein as a strict traffic cop or a brake pedal. Its job is to stop the heart muscle cells from getting too wide.
2. KMT5A (The Architect): This is a builder who tells the cell's DNA to start construction projects. Specifically, it likes to build "wide" cells.
3. H4K20me1 (The Green Light): This is a tiny chemical tag (like a sticky note) placed on the DNA. When KMT5A puts this tag on the DNA, it opens up the "construction site," allowing the genes for "getting wide" to be read and built.

The Plot: How the Switch Works

1. The Normal Situation (The Brake is On)
In a healthy heart, CDC14A is active. It acts like a brake on KMT5A. It keeps KMT5A in check, preventing it from putting too many "Green Light" tags (H4K20me1) on the DNA. Because the tags are low, the genes that make the heart cells grow wide stay quiet. The heart maintains a healthy balance.

2. The Stress Situation (The Brake Fails)
When the heart is stressed (by high blood pressure or bad genes), a signal comes in that tells CDC14A to take a break.

• CDC14A steps away.
• KMT5A is now free to run wild.
• KMT5A floods the DNA with H4K20me1 tags.
• The "Green Light" is on for genes that tell the cell: "Grow wider! Get thicker!"
• Result: The heart becomes a "Thick-Walled Fortress" (Concentric Hypertrophy).

3. The Disease Situation (The Architect is Missing)
Here is the twist: In some forms of heart failure (Dilated Cardiomyopathy), the problem isn't that the brake is stuck; it's that the Architect (KMT5A) is missing or broken.

• If KMT5A is low, there are no "Green Light" tags.
• The genes for growing wide are never turned on.
• Instead, the heart cells just stretch out and get long and thin.
• Result: The heart becomes a "Stretched Balloon" (Eccentric/Dilated Cardiomyopathy).

The Breakthrough Discovery

The researchers found that CDC14A and KMT5A are a team.

• CDC14A normally keeps KMT5A in check.
• If you remove CDC14A (take the brake off), KMT5A goes up, and the heart gets wider.
• If you remove KMT5A (remove the architect), the heart gets thin and weak (Dilated).

The "Aha!" Moment: Fixing the Broken Heart

The most exciting part of the paper is the potential cure.

The researchers used a special virus (a gene therapy tool) to silence CDC14A in mice that had a genetic disease causing a "Stretched Balloon" heart (Dilated Cardiomyopathy).

• What happened? By silencing the "Brake" (CDC14A), they allowed the "Architect" (KMT5A) to wake up.
• The Result: The "Stretched Balloon" heart stopped stretching. It started growing wider again, thickening its walls, and pumping much stronger. The heart's shape and function improved dramatically.

The Takeaway

Think of the heart's shape like a seesaw.

• On one side is CDC14A (the brake).
• On the other side is KMT5A (the builder).

In a healthy heart, they balance each other. In some heart diseases, the builder is missing, and the heart collapses into a weak, stretched shape. This paper suggests that if we can gently press the "brake" (inhibit CDC14A), we can force the builder to wake up and fix the heart's shape, turning a weak, stretched heart back into a strong, functional one.

In simple terms: They found a molecular switch that controls whether the heart gets thick or thin. By flipping this switch in the right direction, they might be able to cure a type of heart failure that currently has very few treatment options.

Technical Summary

1. Problem Statement

Pathological cardiac remodeling manifests primarily in two distinct geometric forms: concentric hypertrophy (increased wall thickness relative to chamber size, often leading to heart failure with preserved ejection fraction) and eccentric hypertrophy (chamber dilation with wall thinning, leading to heart failure with reduced ejection fraction, or HFrEF). While both are associated with heart failure and sudden death, the molecular mechanisms determining whether the heart undergoes concentric or eccentric remodeling remain poorly understood. Previous research identified the ERK1/2-RSK3-SRF pathway as a driver of concentric growth (increased cardiomyocyte width), but the specific downstream effectors and epigenetic regulators controlling the balance between width and length growth were not fully defined.

2. Methodology

The study employed a multi-disciplinary approach combining in vitro cell biology, epigenomics, and in vivo gene therapy models:

• Cell Culture Models: Primary adult rat ventricular myocytes (ARVMs) were used to study morphology. Cells were stimulated with $\alpha$-adrenergic agonists (phenylephrine, PE) or transfected with phosphomimetic Serum Response Factor (SRF S103D) to induce hypertrophy.
• Genetic Manipulation:
  • Loss of Function: RNA interference (siRNA/shRNA) was used to knock down CDC14A, KMT5A, and the demethylase PHF8.
  • Gain of Function: Adenoviral vectors expressed wild-type (WT) and mutant forms of CDC14A (including catalytically inactive C278S) and KMT5A (including phosphomimetic S59D).
• Epigenomic Profiling:
  • CUT&RUN: Used to map genome-wide distribution of Histone 4 Lysine 20 mono-methylation (H4K20me1) and tri-methylation (H4K20me3).
  • PRO-seq (Precision Nuclear Run-On Sequencing): Used to measure nascent pre-mRNA transcription rates to correlate epigenetic marks with gene expression.
• In Vivo Models:
  • Wild-Type Mice: AAV vectors (AAVMYO capsid) expressing KMT5A shRNA were administered to induce cardiac-specific knockdown.
  • Dilated Cardiomyopathy (DCM) Model: Tpm1 E54K (TM54) transgenic mice, which develop DCM, were treated with AAV9 vectors expressing CDC14A shRNA to test therapeutic potential.
• Phenotyping: Echocardiography (M-mode and B-mode), 4D imaging, histology (Wheat Germ Agglutinin staining), and Western blotting were used to assess cardiac geometry, function, and protein levels.

3. Key Contributions

• Identification of CDC14A as a Morphological Brake: The study identifies the protein phosphatase CDC14A as a critical negative regulator of cardiomyocyte growth in width.
• Discovery of the CDC14A-KMT5A Axis: The authors establish that CDC14A dephosphorylates the lysine methyltransferase KMT5A (also known as PR-SET7/Setd8). Dephosphorylation by CDC14A promotes KMT5A nuclear export and degradation. Conversely, reduced CDC14A leads to nuclear accumulation of phosphorylated KMT5A.
• Epigenetic Mechanism: The study links KMT5A activity to H4K20 mono-methylation (H4K20me1). Increased H4K20me1 creates an open chromatin conformation that facilitates the transcription of genes driving concentric remodeling (growth in width).
• Therapeutic Targeting of DCM: The paper demonstrates that inhibiting CDC14A (thereby restoring KMT5A levels) can reverse the pathological eccentric remodeling and systolic dysfunction in a genetic mouse model of Dilated Cardiomyopathy.

4. Key Results

In Vitro Findings

• CDC14A Regulation: $\alpha$-adrenergic stimulation and SRF activation repress CDC14A transcription. Knocking down CDC14A in myocytes mimics PE stimulation, increasing cell width and the width-to-length (W:L) ratio without affecting length.
• KMT5A as an Effector: CDC14A knockdown increases KMT5A protein levels. KMT5A knockdown prevents PE-induced widening of myocytes.
• Phosphorylation State: The KMT5A S59D phosphomimetic mutant (which mimics the state when CDC14A is inactive) localizes to the nucleus and increases the W:L ratio, phenocopying hypertrophy.
• Epigenomic Landscape:
  • H4K20me1 is enriched in intragenic regions (introns/exons), whereas H4K20me3 is intergenic.
  • PE stimulation increases H4K20me1 marks at specific gene loci in a KMT5A-dependent manner.
  • There is a significant statistical association (Odds Ratio = 1.7) between PE-regulated H4K20me1 marks and altered gene transcription.
  • Genes with regulated H4K20me1 marks are enriched for pathways involved in metabolism, signaling, and cardiomyopathy (e.g., Flnc, Mybpc3, Cacna1c).
• Demethylase Validation: Knocking down PHF8 (the H4K20me1 demethylase) increased myocyte width, confirming that elevated H4K20me1 drives concentric growth.

In Vivo Findings

• KMT5A Loss Causes DCM-like Phenotype: Systemic delivery of AAV-shKMT5A to wild-type mice resulted in:
  • Reduced KMT5A protein levels (~40-50%).
  • Systolic dysfunction (decreased fractional shortening and ejection fraction).
  • Eccentric remodeling: Increased LV end-systolic diameter, wall thinning, and decreased relative wall thickness.
  • No significant hypertrophy in the ventricles, but significant left atrial hypertrophy.
• CDC14A Inhibition Treats DCM: In TM54 DCM mice (which have low KMT5A and eccentric remodeling):
  • Administration of AAV-shCDC14A increased KMT5A protein levels by ~40%.
  • Functional Rescue: Ejection fraction improved significantly (from ~28% to ~45%).
  • Structural Rescue: LV wall thickness and relative wall thickness increased; LV volumes normalized.
  • Molecular Rescue: RNA-seq showed that CDC14A inhibition reversed the gene expression profile of TM54 mice, normalizing 1,840 differentially expressed genes. Notably, genes with PE-regulated H4K20me1 sites showed a strong inverse correlation between disease state and treatment.

5. Significance and Clinical Implications

• Mechanistic Insight: This study defines a novel "molecular switch" (CDC14A-KMT5A-H4K20me1) that dictates whether the heart remodels concentrically or eccentrically. It bridges the gap between signaling pathways (ERK/SRF) and the epigenetic machinery controlling chromatin accessibility.
• Therapeutic Potential for HFrEF: Dilated Cardiomyopathy (DCM) and Heart Failure with Reduced Ejection Fraction (HFrEF) are major causes of mortality with limited disease-modifying therapies. The finding that inhibiting CDC14A restores KMT5A and reverses eccentric remodeling suggests CDC14A is a viable therapeutic target for HFrEF.
• Etiology-Agnostic Approach: Since the pathway regulates the fundamental balance of cardiomyocyte geometry, targeting CDC14A may be effective across diverse genetic causes of DCM, not just the specific Tpm1 mutation used in the study.
• Caution for Cancer Therapy: KMT5A inhibitors are currently being developed for cancer. This study suggests that systemic KMT5A inhibition could inadvertently induce a DCM-like phenotype, highlighting a potential cardiac toxicity risk for oncology patients.

In conclusion, the paper elucidates a critical epigenetic pathway where CDC14A acts as a brake on KMT5A-mediated H4K20me1 to prevent pathological widening of cardiomyocytes. Restoring this balance via CDC14A inhibition offers a promising strategy to treat dilated cardiomyopathy.